Measuring progression of nigrostriatal degeneration in Parkinson’s disease using 18F-AV-133 vesicular monoamine transporter type-2 (VMAT2) PET
Objective: To evaluate the progression of nigrostriatal degeneration in participants with Parkinson’s disease (PD) using 18F-AV-133 vesicular monoamine transporter type-2 (VMAT2) PET. Background: Vesicular monoamine…Imaging correlates of impaired self-awareness of cognitive deficits in Parkinson’s disease
Objective: To discover the neural basis of impaired self-awareness of cognitive deficits (ISA-cog) in Parkinson’s disease (PD) patients with mild cognitive impairment (MCI). Background: Anosognosia…The Dutch Parkinson and Cognition study (DUPARC): Cognitive impairment and cholinergic innervation in de novo Parkinson’s Disease patients
Objective: To explore the incidence and characteristics of early cognitive impairment in Parkinson’s disease (PD) patients and the relationship with regional cholinergic innervation. Background: Cognitive…Brain amyloid contribution to cognitive dysfunction in Lewy bodies disorders: a pilot study
Objective: To investigate regional [18F]florbetapir binding to amyloid-β and its contribution to cognitive dysfunction in Lewy bodies disorders. Background: Lewy bodies disorders like Parkinson’s disease…Molecular correlates of survival and clinical severity in Progressive Supranuclear Palsy
Objective: To test how regional tau pathology and neuroinflammation are associated with clinical severity and survival in progressive supranuclear palsy (PSP). Background: The abnormal aggregation…Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s Disease: An in vivo [11C]BU99008 PET study
Objective: We aimed to evaluate the role of astroglia activation in Parkinson's disease (PD) using [11C]BU99008 PET, a novel radioligand with high specificity and selectivity…Visual hallucinations in Parkinson´s disease and amyloid burden: 18F-Flutemetamol PET-MRI study
Objective: To compare amyloid distribution in patients with Parkinson´s disease (PD) with visual hallucinations (VH-p) and without (VH-n). Background: In patients with PD the prevalence…Is 18F-FDG-PET/CT a helpful tool to diagnose PSP clinical variants?
Objective: To assess if there are differential metabolic brain patterns among Progressive Supranuclear Palsy(PSP) clinical variants and between them and Parkinson’s disease patients (PD). Background:…Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Huntington’s Disease: An in vivo [11C]BU99008 PET study
Objective: We aimed to evaluate the role of astroglia activation in Huntington’s disease gene expansion carriers (HDGECs) using [11C]BU99008 PET, a novel radioligand with high specificity and…Functional connectivity and microstructural alterations in regions of synaptic density loss in DLB and PDD
Objective: We aimed to investigate whether functional connectivity and white matter integrity is altered in regions exhibiting reduced synaptic density, as measured by [11C]UCB-J-PET,in Dementia with…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 40
- Next Page »